Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study

Prostate International - Tập 3 - Trang 22-26 - 2015
Dalsan You1, Byung Ha Chung2, Sang Eun Lee3, Choung-Soo Kim1
1Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
2Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, South Korea
3Department of Urology, Seoul National University Bundang Hospital, Seongnam, South Korea

Tài liệu tham khảo

2013

Van Poppel, 2012, Gonadotropin-releasing hormone: an update review of the antagonists versus agonists, Int J Urol, 19, 594, 10.1111/j.1442-2042.2012.02997.x

Klotz, 2008, The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer, BJU Int, 102, 1531, 10.1111/j.1464-410X.2008.08183.x

Yasuda, 2008, The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies, Clin Pharmacol Ther, 84, 417, 10.1038/clpt.2008.141

O'Donnell, 2009, Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy, Clin Cancer Res, 15, 4806, 10.1158/1078-0432.CCR-09-0344

Pettaway, 1999, Racial differences in the androgen/androgen receptor pathway in prostate cancer, J Natl Med Assoc, 91, 653

Ozono, 2012, The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer, Jpn J Clin Oncol, 42, 477, 10.1093/jjco/hys035

Wu, 1995, Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada, Cancer Epidemiol Biomarkers Prev, 4, 735

Song, 2006, Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy, Urology, 68, 820, 10.1016/j.urology.2006.04.029

Salonen, 2008, Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation, J Urol, 180, 915

Weckermann, 2004, Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues, Eur Urol, 46, 279, 10.1016/j.eururo.2004.05.006

Van Poppel, 2008, Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker–results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer, Eur Urol, 54, 805, 10.1016/j.eururo.2008.04.065

Gittelman, 2008, A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America, J Urol, 180, 1986

Thompson, 2001, Flare associated with LHRH-agonist therapy, Rev Urol, 3, S10

Heidenreich, 2013

Tombal, 2005, How good do current LHRH agonists control testosterone? Can this be improved with Eligard?, Eur Urol Suppl, 4, 30, 10.1016/j.eursup.2005.08.004

Berges, 2006, Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer, Curr Med Res Opin, 22, 649, 10.1185/030079906X96425

Morote, 2007, Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy, J Urol, 178, 1290

Thông tin
Thông tin xuất bản

Prostate International

Tập 3

22-26

Thông tin tác giả